title: An oxaliplatin + 5-fluorouracil bolus + folinic acid (BFOL) regimen as first-line treatment in metastatic colorectal cancer patients.
abstract: OBJECTIVE
  The purpose of the study was to evaluate the outcome of metastatic colorectal cancer patients treated, as first line, with 5-fluorouracil bolus/leucovorin + oxaliplatin, in terms of response, progression-free and overall survival.
  
  
  METHODS
  A retrospective cohort of consecutive metastatic colorectal cancer patients, treated from 2003 to 2006, was identified and analyzed. All patients, without a central venous device, were treated with oxaliplatin + 5-fluorouracil and leucovorin.
  
  
  RESULTS
  Twenty-five metastatic colorectal cancer patients were treated. No 3-4 grade toxicity was observed. Five of 23 patients achieved a partial response: one of them resulted in a complete response after radiofrequency and another one after surgery. Fifteen of 23 patients had stable disease (one underwent radical surgery after chemotherapy, obtaining a complete remission) and 3 had progressive disease. Median progression-free survival was 7.2 months, and median overall survival was 30 months.
  
  
  CONCLUSIONS
  Based on this case-series study, the regimen seems to offer a good control of disease (86.9%) and can be considered as an alternative choice for patients who cannot receive continuous infusion.
authors.affiliation: Oncology Department, Azienda Ospedaliera Ospedale Fatebenefratelli e Oftalmico, Milan, Italy. nicla.laverde@fbf.milano.it
authors.forename: Nicla
authors.initials: N
authors.lastname: La Verde
authors.forename: Marina
authors.initials: M
authors.lastname: Garassino
authors.forename: Claudia
authors.initials: C
authors.lastname: Bareggi
authors.forename: Paola
authors.initials: P
authors.lastname: Sburlati
authors.forename: Karen
authors.initials: K
authors.lastname: Borgonovo
authors.forename: Mariastella
authors.initials: M
authors.lastname: Dimaiuta
authors.forename: Cristina
authors.initials: C
authors.lastname: Mantica
authors.forename: Silvia
authors.initials: S
authors.lastname: Perrone
authors.forename: Valter
authors.initials: V
authors.lastname: Torri
authors.forename: Gabriella
authors.initials: G
authors.lastname: Farina
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007275:Injections, Intravenous; D053208:Kaplan-Meier Estimate; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D002955:Leucovorin; D005472:Fluorouracil